PE20250401A1 - Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias - Google Patents

Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias

Info

Publication number
PE20250401A1
PE20250401A1 PE2024003046A PE2024003046A PE20250401A1 PE 20250401 A1 PE20250401 A1 PE 20250401A1 PE 2024003046 A PE2024003046 A PE 2024003046A PE 2024003046 A PE2024003046 A PE 2024003046A PE 20250401 A1 PE20250401 A1 PE 20250401A1
Authority
PE
Peru
Prior art keywords
alkyl
formula
pyrazolo
auto
treatment
Prior art date
Application number
PE2024003046A
Other languages
English (en)
Spanish (es)
Inventor
Fabian Dey
Xin Hong
Xiaoqing Wang
Zhisen Zhang
Wei Zhu
Ge Zou
Dongdong Chen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20250401A1 publication Critical patent/PE20250401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2024003046A 2021-09-24 2022-09-22 Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias PE20250401A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021120406 2021-09-24
CN2022089033 2022-04-25
PCT/EP2022/076306 WO2023046806A1 (en) 2021-09-24 2022-09-22 Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
PE20250401A1 true PE20250401A1 (es) 2025-02-11

Family

ID=83688579

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2024003046A PE20250401A1 (es) 2021-09-24 2022-09-22 Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades auto/inmunitarias
PE2024000482A PE20240815A1 (es) 2021-09-24 2022-09-22 Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2024000482A PE20240815A1 (es) 2021-09-24 2022-09-22 Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias

Country Status (16)

Country Link
US (1) US20240360126A1 (cg-RX-API-DMAC10.html)
EP (1) EP4405051B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024534567A (cg-RX-API-DMAC10.html)
KR (1) KR20240065092A (cg-RX-API-DMAC10.html)
CN (1) CN118076604A (cg-RX-API-DMAC10.html)
AR (1) AR127126A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022351495A1 (cg-RX-API-DMAC10.html)
CA (1) CA3228485A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000791A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024003401A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240134A (cg-RX-API-DMAC10.html)
IL (1) IL310443A (cg-RX-API-DMAC10.html)
MX (1) MX2024003444A (cg-RX-API-DMAC10.html)
PE (2) PE20250401A1 (cg-RX-API-DMAC10.html)
TW (1) TW202328129A (cg-RX-API-DMAC10.html)
WO (1) WO2023046806A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026515029A (ja) * 2023-04-28 2026-05-13 成都思倍博医▲薬▼科技有限公司 オキソピリド脂肪族環又は脂肪族複素環構造を含む化合物及びその医学的使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9643967B2 (en) * 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
EP4059934B1 (en) 2016-09-09 2026-07-29 Novartis AG Compounds and compositions as inhibitors of endosomal toll-like receptors
JP2021507889A (ja) * 2017-12-22 2021-02-25 ノバルティス アーゲー ピラゾロピペリジン誘導体の新規な使用
WO2019220390A1 (en) 2018-05-18 2019-11-21 Novartis Ag Crystalline forms of a tlr7/tlr8 inhibitor
CN112752755A (zh) * 2018-09-27 2021-05-04 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的杂环基化合物
JP2023533807A (ja) * 2020-07-14 2023-08-04 エフ. ホフマン-ラ ロシュ アーゲー 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物

Also Published As

Publication number Publication date
KR20240065092A (ko) 2024-05-14
EP4405051A1 (en) 2024-07-31
TW202328129A (zh) 2023-07-16
CL2024000791A1 (es) 2024-09-06
AU2022351495A1 (en) 2024-02-01
PE20240815A1 (es) 2024-04-18
CN118076604A (zh) 2024-05-24
CO2024003401A2 (es) 2024-04-29
JP2024534567A (ja) 2024-09-20
AR127126A1 (es) 2023-12-20
MX2024003444A (es) 2024-04-03
EP4405051B1 (en) 2026-07-15
US20240360126A1 (en) 2024-10-31
WO2023046806A1 (en) 2023-03-30
CR20240134A (es) 2024-05-07
CA3228485A1 (en) 2023-03-30
IL310443A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
CA2883751C (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
PE20242113A1 (es) Compuestos de quinolina como inhibidores de kras
EA200702445A1 (ru) Соединения тиазола и способы их применения
EA200601281A1 (ru) Азабензофуранзамещенные тиомочевины; ингибиторы репликации вирусов
EA200602130A1 (ru) Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
PE20030823A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
SG11201809859VA (en) Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
BRPI0510414A (pt) uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos
EA200500846A1 (ru) Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации
CO2023004420A2 (es) Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
AR040673A1 (es) Inhibidores micobacterianos, composicion farmaceutica y proceso de preparacion del compuesto
CA2671470A1 (en) Powder formulation for valganciclovir
ES2701087T3 (es) Derivados de [1,2,4]-triazolo-[1,5-a]-pirimidina como inhibidores del proteasoma de protozoarios para el tratamiento de enfermedades parasitarias tales como leishmaniasis
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
MX2019013383A (es) Agente terapeutico para la demencia que combina derivado de pirazoloquinolina y memantina.
MX2025012439A (es) Composiciones y metodos para el tratamiento de lesion por reperfusion o hemorragia despues de la terapia de recanalizacion
PH12020551772A1 (en) Oxo-substituted compound
KR20120048697A (ko) 폭스바이러스 감염의 치료 방법
NZ761680A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
CA2487252A1 (en) Esters in position 20 of camptothecins
ES2158223T3 (es) Utilizacion de derivados de hidantoina para la preparacion de un medicamento para el tratamiento de las enfermedades asociadas con la presencia de oxigeno activo y de radicales libres.